Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 16/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 16/20 | 1.00 |
| ▸ | NQO2 | P16083 | 3/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31543713 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL18239837 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL18222560 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL5439854 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL31530480 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL31530479 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL3227065 | 0.87 | MTNR1A (0.77) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL3221458 | 0.86 | KDM4E (0.84) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL1774151 | 0.86 | NQO2 (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL1311849 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5552428-A | ANTIARRHYTHMIA AGENTS FOR CARDIOVASCULAR DISORDERS USING MELATONIN DERIVATIVES | INSTITUTO FARMACOLOGICO LOMBARDO-IFLO, S.A.S. (IT) | 1996-09-03 | — | — | US | claimed |
| CN-1017426-B | Process for preparing alkyl melatonin | LILLY CO ELI (US) | 1992-07-15 | — | — | CN | claimed |
| CN-88100478-A | alkyl melatonin | — | 1988-08-17 | — | — | CN | claimed |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20090264521-A1 | Percutaneous absorption preparation | SUZUKI YASUYUKI | 2009-10-22 | — | — | US | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| CN-1047936-C | Method for producing pharmaceutical composite containing alkylmelatonins | LILLY CO ELI (US) | 2000-01-05 | — | — | CN | disclosed |
| US-5552428-A | ANTIARRHYTHMIA AGENTS FOR CARDIOVASCULAR DISORDERS USING MELATONIN DERIVATIVES | INSTITUTO FARMACOLOGICO LOMBARDO-IFLO, S.A.S. (IT) | 1996-09-03 | — | — | US | disclosed |
| CN-1064807-A | Preparation contains the method for the pharmaceutical composition of Alkylmelatonins | LILLY CO ELI (US) | 1992-09-30 | — | — | CN | disclosed |
| CN-1017426-B | Process for preparing alkyl melatonin | LILLY CO ELI (US) | 1992-07-15 | — | — | CN | disclosed |
| CN-88100478-A | alkyl melatonin | — | 1988-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264521-A1 | Percutaneous absorption preparation | MTNR1A, MTNR1B, NPSR1 | MTNR1A 1/4885MTNR1B 2/4885NQO2 2145/4885 |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885NQO2 1994/4885 |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | MTNR1A, GAP43, DCX | MTNR1A 1/4885MTNR1B 4/4885NQO2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.